Mikrobiomik is a biopharmaceutical company born for the research, development, production and commercialization of biologic medicines based on the human microbiome.
At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently with no therapeutic alternative.
Our first investigational biological drug, MBK-01, aimed at the treatment of intestinal infection by Clostridioides difficile, has announced the closure of the phase III clinical trial, and patient recruitment has been completed in November 2023. The regulatory dossier will be presented to the EMA (European Medicines Agency) in 2024, via a centralized channel and its commercialization is expected during the first half of 2025.